Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
about
Smallpox vaccines for biodefense: need and feasibilityThe evolution of poxvirus vaccinesHuman MonkeypoxDevelopment of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infectionSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesModeling the Effect of Herd Immunity and Contagiousness in Mitigating a Smallpox Outbreak.Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.A novel highly reproducible and lethal nonhuman primate model for orthopox virus infectionApplication of the Ibis-T5000 pan-Orthopoxvirus assay to quantitatively detect monkeypox viral loads in clinical specimens from macaques experimentally infected with aerosolized monkeypox virus.A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus.Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challengeA protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines.Poxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primatesGenomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain.Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route.Smallpox vaccines: targets of protective immunity.Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni).Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switchingIMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox.Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infectionDevelopment of ST-246® for Treatment of Poxvirus Infections.Evaluation of monkeypox disease progression by molecular imagingSmall particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsSequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus.Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease.Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesDevelopment of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice
P2860
Q22305942-5246E0D2-B9A1-4FE5-8BEC-81AC1054D039Q26995905-1B3B23A9-1241-4A05-B877-92E4A2903DA9Q27023061-77E13878-84E1-44DB-A2A7-44F3B2D0A8ECQ27321985-00B9C286-E652-4878-8897-62AE9279696EQ27325586-E69BBF87-41EA-4BD9-93F8-56F7E3C8EC8DQ30205740-5E91D496-BF8A-4D6E-8DAA-692749C073A8Q30231576-1CC46BA9-926A-4B42-AA3E-AF7A524C6EF0Q30445071-F3890FBC-5805-47FF-8D6E-158BB907A54DQ33573571-9CEAC5AD-5DDB-439A-9F39-EB44BD97E7C2Q33617625-B6CF2487-8B6B-447D-83ED-3D1FB11645F6Q33624420-FF5BFD07-758B-45ED-B32A-54672B373C1DQ33700318-5349A774-EFDC-4E66-BBD5-5092944B973FQ34092845-C8DEC2BC-DC94-4EA8-ADFB-368F8A600BE7Q34126697-29C9EDA3-A6D0-4A70-A103-FFE53502C0D4Q34188464-8679D468-6A99-4029-9A1E-4B9B76029772Q34556632-C7B189D6-27F4-4544-89EE-3C9458BBC520Q34663791-88E83839-E73C-4583-B6C7-67C8E2307FFCQ34673390-E5A84B2B-887D-4AFB-9BF9-235542ED889BQ34742139-FB0B9D1C-847A-4656-A853-0F060A6629FBQ34780607-96CDA25F-B91A-40EE-BCCD-28B2C0B9C30DQ34791242-12A6FE94-8544-473A-86F4-307DE2927E01Q34810232-E3B8670D-A560-437C-ADE2-90410432DC97Q34907430-52004037-706E-41AE-88B9-38BB430BC9E3Q35023778-E31EFBDC-B080-443F-9CDD-6F6A86F77C8CQ35076706-11F072F3-B191-468B-9EB7-28128936F98AQ35152092-F46D0938-6635-48B5-A0C2-584E9676A8A8Q35189550-91110C08-EF84-4362-87D3-9AC16F2235BEQ35192707-94E4A8AF-84C8-41D3-9CF4-86DA05138A25Q35260385-00F1F6E3-96C3-45F5-BC03-23A7BC20744EQ35532858-BE07A317-390E-4C8E-BB98-9A1C656E2A0AQ35578840-76E3B4C2-C769-4CA9-83D4-ECF86D27B71DQ35634159-92681D66-B062-45C4-9D51-E2FB5AA55938Q35640911-C22BC8AF-AD13-41E2-86B8-105952E3E17DQ35683735-E02A6662-8C60-41F7-8E7A-583055B531DDQ35760869-FD1C8927-1A81-4774-B9BA-A1ECC993640FQ35800226-A6F2BDEC-25EE-435C-9193-DF721B872EF5Q35826728-605487B9-B093-4D6B-81FD-BD91C31DF42CQ35844057-D41A7F43-81F3-4C53-A1CD-0C4E3502314FQ35928588-2A9115E2-A5D4-48B8-80D2-F8A1AE77CB6CQ35947780-6E13EF87-7AF6-40C5-A2BA-E3803100D7EF
P2860
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Modified vaccinia virus Ankara ...... hallenge with monkeypox virus.
@en
type
label
Modified vaccinia virus Ankara ...... hallenge with monkeypox virus.
@en
prefLabel
Modified vaccinia virus Ankara ...... hallenge with monkeypox virus.
@en
P2093
P2860
P1433
P1476
Modified vaccinia virus Ankara ...... hallenge with monkeypox virus.
@en
P2093
Ben A M van der Zeijst
Frank H M Pistoor
Geert van Amerongen
Gerard van Doornum
Hubert G M Niesters
Ivanela Kondova
Koert J Stittelaar
Luis Mateo
Paul J Chaplin
Rob F van Lavieren
P2860
P304
P356
10.1128/JVI.79.12.7845-7851.2005
P577
2005-06-01T00:00:00Z